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Purpose: Preservation of renal function is of paramount importance in patients with 
tumors in solitary kidneys. We compared the renal function and oncologic outcomes 
of patients treated by partial nephrectomy with those of patients treated by cryoa-
blation for solitary kidney tumors.
Materials and Methods: All patients with solitary kidneys who were treated for renal 
tumors at our institution between 1997 and 2007 were included in the screen. We retro-
spectively identified 23 patients who underwent cryoablation and 15 patients who un-
derwent partial nephrectomy.
Results: The two groups were similar with regard to age, gender, and tumor laterality. 
Patients in the partial nephrectomy group had a larger tumor size (3.4 cm vs. 2.5 cm, 
p=0.01), higher mean estimated blood loss (316 cc vs. 87 cc, p＜0.001), longer duration 
of hospital stay (5.8 vs. 1.8 days, p＜0.001), and a higher rate of perioperative complica-
tions (53.3% vs. 8.7% patients, p=0.03). Percentage changes in the glomerular filtration 
rate postoperatively and on follow-up were found to be similar in the two groups. Both 
the cryoablation and the partial nephrectomy groups with mean follow-ups of 31.2 
months and 30.8 months, respectively, had evidence of local or distant recurrence in 
3 patients each (13% and 20% respectively, p=0.7). Both groups had a similar mean 
overall survival (88.9 and 86.9 months in the cryoablation and partial nephrectomy 
groups, respectively, p=0.8).
Conclusions: For tumors in solitary kidneys, renal functional and clinical outcomes for 
cryoablation were not significantly different from those for partial nephrectomy. 
However, cryoablation has the distinct advantage of a lower morbidity rate and can 
be preferentially offered to selected cases.
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INTRODUCTION
A surgically resectable tumor in an anatomically or func-
tionally solitary kidney is an absolute indication for neph-
ron-sparing surgery (NSS) [1]. The aim of NSS is to max-
imize local tumor extirpation with optimal preservation of 
renal function to prevent the development of end-stage re-
nal disease. Partial nephrectomy (PN) remains the treat-
ment of choice, and encouraging oncologic outcomes in soli-
tary kidney patients have been reported by several groups 
[1-3]. However, because it requires renal hilar clamping 
with possible renal ischemia, PN can have deleterious ef-
fects on renal function. Cryoablation offers nephron-spar-
ing management of renal masses with fewer technical chal-
lenges, favorable oncologic results, shorter convalescence, 
and minimal parenchymal loss [4-6]. The feasibility and ef-
ficacy of cryoablative therapy for the management of tu-
mors in solitary kidney patients has been reported earlier 
[7]. However, sufficient data are lacking comparing the im-
pact on renal function and oncologic outcomes of the two Korean J Urol 2011;52:384-389
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TABLE 1. Patient demographics, tumor characteristics, and perioperative data
Cryoablation Partial  nephrectomy p-value
No. of patients 23 15
Gender (male/fmale) 13/10 13/2 0.051
Mean age in years (range) 68.4 (39.8-79.4) 65.2 (47.2-85.3) 0.39
Co-morbidities -
　Hypertension (%) 17 (73.9) 10 (66.6)
　Hyperlipidemia (%) 13 (56.5) 6 (40)  
　Diabetes (%)   4 (17.4)   4 (26.6)
　Heart disease (CAD/CHF) (%) 3 (13) 6 (40)  
Mean charlson comorbidity index
a 3.5 3.2 0.59
CKD (GFR＜60 ml/min/1.73 m
2) 15 (65.2) 9 (60)   0.91
Mean tumor size in cm (range)  2.5 (1-4) 3.4 (1-5.5) 0.01
Tumor location 0.68
　Upper pole (%)   7 (30.4) 3 (20)  
　Middle (%) 12 (52.2)   8 (53.3)
　Lower pole (%)   4 (17.4)   4 (26.7)
Tumor histology 0.81
　Renal cell carcinoma (%)   18 (78.26)  12 (80)
　　Clear cell (%) 15 10
　　Papillary (%)   3   2
　Benign (%) 5 (21.74)  3 (20)  
　　Angiomyolipoma   2 -
　　Cyst   2   2
　　Oncocytoma   1   1
Surgical approach -
　Laparoscopic (%)   8 (34.8)   2 (13.3)
　Open (%)   4 (17.4) 13 (86.7)
　Percutaneous (%) 11 (47.8) -
Mean hospital stay in days (range)  1.8 (1-9) 5.8 (2-15)   ＜0.001
Mean estimated blood loss in cc  87±105.7 316±528.3 ＜0.001
Mean duration of 1st freeze in minutes 9.9 N/A -
Mean duration of 2nd freeze in minutes 9.6 N/A -
No. of probes used  -
　1 (%) 12 (52.2) N/A
　2 (%)   6 (26.1) N/A
　3 (%) 3 (13)  N/A
　4 (%) 2 (8.7) N/A
Mean follow-up in months (range) 31.2 (0.6-153) 30.8 (0.1-113.5) 0.97
Dialysis (%) 1 (4.3)   2 (13.3) 0.31
Recurrence (%) 3 (13)   3 (20)   0.70
No. of patients with complications (%) 2 (8.7)   8 (53.3) 0.03
Complications (n) Atrial flutter (1) Atrial flutter (2)
Sinus tachycardia (1) Ureteral transection (1)
Myocardial infarction (1)
Pneumonia (1)
Pulmonary edema (1)
Cholestatic jaundice (1)
Flank cellulitis (1) 
Bullous impetigo (1)
Wound infection (1)
CAD: coronary artery disease, CHF: congestive heart failure, CKD: chronic kidney disease, GFR: glomerular filtration rate, 
a: calculated
by using the parameters defined in the original publication [13]
procedures in this specific subset of patients. In this article, 
we present the experience of a single institution with pa-
tients undergoing cryoablation and compare renal func-
tional outcomes with those who underwent PN for such tu-
mors. The data were collected retrospectively and analyzed.
MATERIALS AND METHODS
After obtaining the approval of the Institutional Review 
Board, we examined the medical records between 1997 and 
2007 of all patients who underwent NSS for small, localized 
renal masses in a solitary kidney. The choice of procedure Korean J Urol 2011;52:384-389
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TABLE 2. Renal functional outcomes after nephron-sparing sur-
gery
Cryoablation
Partial 
nephrectomy
p-value
Serum creatinine 
(mg/dl)
　Preoperative 1.3±0.4   1.5±0.7 0.20
　Postoperative 1.33±0.4   1.9±0.7 0.02
Estimated GFR
a
　Preoperative 54.6±16.5 55.07±22.2 0.95
　Postoperative 51.9±16.5 43.5±18 0.21
　% decrease   4.7±15.9   17.7±26.7 0.1
Blood urea nitrogen 
(mg/dl)
　Preoperative   24.7±9.8   27.6±19.5 0.35
　Postoperative   20.2±9.1   26.6±15.6 0.19
Pretreatment CKD 15 (65.2%) 9 (60%) 0.91
De novo post treatment
CKD
 2 (25%) 2 (33%) 0.86
CKD: Chronic kidney disease, 
a: glomerular filtration rate (GFR)
in ml per minute per 1.73 m
2 estimated using modification of diet
in renal disease (MDRD) equation [15]
TABLE 3. Outcomes of pretreatment and de novo chronic kidney 
disease
Cryoablation
Partial 
nephrectomy
Patients with pretreatment 
CKD before NSS
15 (65.2%)  9 (60%)
　Before NSS
　　Hypertension 10 (66.6%) 6 (66.6%)
　　Hyperlipidemia 11 (73.3%) 4 (44.4%)
　　Diabetes   4 (26.6%) 2 (22.2%)
　　Heart disease (CAD/CHF)   2 (13.3%) 5 (55.5%)
　After NSS at last follow-up
　　Hypertension 11 (73.3%) 7 (77.7%)
　　Hyperlipidemia 11 (73.3%) 5 (55.5%)
　　Diabetes   5 (33.3%) 2 (22.2%)
　　Heart disease (CAD/CHF)   4 (26.6%) 6 (66.6%)
Patients with de novo CKD 
after NSS 
  3 (37.5%) 2 (33.3%)
　Hypertension  3 (100%)  1 (50%)
　Hyperlipidemia   1 (33.3%) 0
　Diabetes 0  1 (50%)
　Heart disease (CAD/CHF)   1 (33.3%) 0
CKD: Chronic kidney disease, NSS: Nephron sparing surgery, 
CAD: Coronary artery disease, CHF: Congestive heart failure
(cryoablation or PN) and the approach (open, laparoscopic, 
or percutaneous) were chosen on the basis of tumor charac-
teristics, co-morbid conditions, patient preference, and 
surgeon discretion. The technique used for cryoablation 
has been described earlier by many authors [8-10]. An in-
traoperative ultrasound was used for laparoscopic and 
open cryoablation for tumor confirmation and monitoring 
of ice ball formation. Percutaneous cryoablation was done 
under computed tomography (CT) guidance. Both open and 
laparoscopic partial nephrectomy (OPN and LPN) were al-
so performed by using standard techniques as described 
previously [11,12]. 
　The clinical features studied included patient demo-
graphics, perioperative details, and follow-up data. Radiol-
ogy and pathology reports were reviewed for tumor size, lo-
cation, and histological subtype. Comorbidities were com-
pared by using the Charlson Comorbidity Index [13]. Renal 
function was assessed by calculating the glomerular filtra-
tion rate (GFR) from serum creatinine (sCr) values by using 
the modification of diet in renal disease (MDRD) formula 
[14]. Chronic kidney disease (CKD) was defined as a GFR 
of less than 60 ml/min/1.73 m
2. De novo CKD developed 
when the baseline renal function was normal but post-
surgical GFR was abnormal on two separate occasions. All 
complications that occurred during the surgery or up to 30 
days after the surgery were identified from the patients’ 
medical records and evaluated. The patients were periodi-
cally followed up to look for any evidence of recurrence on 
CT imaging.
　Statistical analysis was done by using SPSS ver. 17.0 
(SPSS Inc., Chicago, IL, USA). Descriptive statistics are 
presented as the mean±SD and percentages. Mann-Whitney 
U tests were used to compare means and Fisher’s exact test 
was used to compare proportions. A p-value of less than 
0.05 was considered statistically significant. Kaplan Meier 
survival curves were drawn for each group, and the log rank 
test was used to test for differences in survival.
RESULTS
Of the 38 patients with a renal mass in their solitary kid-
ney, 23 underwent cryoablation and 15 underwent PN. The 
patient demographics, tumor characteristics, and peri-
operative details are listed in Table 1. No significant differ-
ences between the two groups were found with respect to 
age, gender, and tumor laterality. However, patients who 
underwent PN had a higher mean tumor size than did the 
cryoablation group (3.4 cm vs. 2.5 cm, p=0.01). The mean 
estimated blood loss (EBL) during the procedure was also 
significantly higher in the PN group (316 cc vs. 87 cc re-
spectively, p＜0.001). Blood transfusion was not required 
in any patient who underwent cryoablation and was re-
quired in only 1 patient undergoing PN. Patients who un-
derwent PN had a longer mean duration of hospital stay 
(5.8 days vs. 1.8 days, p＜0.001) and a higher rate of peri-
operative complications (53.3% and 8.7% patients, re-
spectively, p=0.03). Two patients (13.3%) in the PN group 
reported more than one complication. 
　In the comparison of the effect on the GFR (as shown in 
Table 2), there was a trend toward a better preserved GFR 
in the cryoablation group; however, this effect did not reach 
statistical significance between the two groups for percent-
age changes in the values on postoperative day 1 (p=0.1) 
or on follow-up (p=0.07). Chronic kidney disease was seen Korean J Urol 2011;52:384-389
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FIG. 1. Kaplan-Meier estimated mean overall survival curves af-
ter cryoablation and partial nephrectomy in patients with tumors
in solitary kidneys (log rank test p=0.8).
in 15 patients (65.2%) in the cryoablation group and in 9 
patients (60%) in the PN group at the time of surgery. Table 
3 outlines the morbidities associated with CKD, including 
hypertension, hyperlipidemia, diabetes, and heart disease. 
De novo development of CKD was seen in 3 of 8 patients 
(37.5%) in the cryoablation group and 2 of 6 patients (33.3%) 
in the PN group. 
　The patients were followed up for a mean period of 31.2 
months in the cryoablation group and 30.8 months in the 
PN group. No statistical difference was observed in the rates 
of progression of disease, which was seen in 3 patients each 
(13% and 20% in the cryoablation and PN groups, re-
spectively, p=0.7). The mean tumor size in patients who 
showed disease progression on follow-up was 2.1 cm in the 
cryoablation group and 4.5 cm in the PN group. In the cryoa-
blation group, 2 of the patients developed distant meta-
stases to the pancreas and the lungs. One of these patients 
received therapy with IL-2 and Temsirolimus, but ulti-
mately succumbed to the disease 2 years later. The second 
patient was put on Sunitinib therapy, but was lost to fol-
low-up. The third patient had a local recurrence of the tu-
mor at the cryoablation site and underwent a radical 
nephrectomy. This patient required dialysis thereafter. 
Local recurrence of disease occurred in 2 patients in the PN 
group, both of whom were treated with subsequent cryo-
ablation. The third patient had multiple metastatic pulmo-
nary nodules and died shortly thereafter following a rapid 
deterioration of pulmonary function. Hemodialysis was re-
quired in 2 patients (13.3%) in this group after the pro-
cedure. One of them developed end-stage renal disease im-
mediately after PN on removal of a large tumor burden. The 
second patient required hemodialysis after a nephrour-
eterectomy done for a transitional cell carcinoma 1 year af-
ter the initial procedure. The estimated mean overall sur-
vival of 88.9 months in the cryoablation group was similar 
to the 86.9 months in the PN group (p=0.8 on log rank test) 
(Fig. 1).
DISCUSSION
Tumors in a solitary kidney represent an oncologic 
challenge. Partial nephrectomy is the first-line option for 
the management of such tumors. Numerous studies have 
shown promising cancer-specific outcomes along with ad-
equate preservation of renal function in solitary kidney tu-
mors treated with PN [1-3]. LPN and OPN were shown to 
be similar with regard to oncologic efficacy and renal func-
tional outcomes in a multicenter study [15]. The duration 
of renal ischemia required during PN is the single most im-
portant modifiable risk factor for renal function main-
tenance [16]. The impact of ischemia and subsequent re-
perfusion injury has been studied by some groups. Beri et 
al used a combination of creatinine clearance time, peak 
concentration time, and MAG 3 isotope clearance to accu-
rately evaluate postoperative parenchymal function [17]. 
Another group used the duration of renal parenchymal re-
tention of MAG 3 as a tool to assess ischemic renal damage 
[18]. It is in keeping with these concerns that PN without 
ischemia has been gaining popularity in recent years 
[19,20].
　Cryoablation, which completely avoids hilar clamping 
and the subsequent renal ischemic insult, is indicated in 
patients who are elderly, in patients who are poor surgical 
candidates owing to comorbidities or previous surgical his-
tory, and in patients with solitary kidneys [9]. Many stud-
ies have shown that cryoablation is technically less chal-
lenging, has a shorter duration of hospital stay, and is asso-
ciated with improved convalescence [4-6]. Therefore, cry-
oablation is now being offered to many patients with cort-
ical tumors less than 3 cm in size [6,21]. However, there is 
a dearth of literature comparing preservation of renal func-
tion and oncologic outcomes between PN and cryoablation 
in the specific cohort of patients with solitary kidney tu-
mors. 
　Because a solitary kidney is the most significant risk fac-
tor for acute renal failure after NSS [22], preservation of 
renal function assumes a very important role while choos-
ing the preferred mode of treatment. Deteriorating renal 
function is associated with an increased risk of cardiovas-
cular morbidity, hospital admissions, and mortality [23]. 
We used the MDRD formula to estimate renal function. 
Other equations like the Cockcroft-Gault and CKD-EPI 
have also been shown to accurately estimate the GFR [24- 
26]. In two different studies, Desai et al and O’Malley et al 
compared the percentage changes in renal function be-
tween PN and cryoablation and found that they were sim-
ilar [27,28]. A study by Turna et al showed that in solitary 
kidneys, the decrease in GFR caused by PN was significantly 
more than that caused by ablative techniques [29]. Com-
pared with this, we found that the percentage change in the 
GFR postoperatively and on follow-up was not statistically 
different in the two groups. Although the mean values in-
dicate a trend toward lesser impact on the GFR for cryoa-
blation, the p-value (0.07) did not reach significance, likely 
representing inadequate power to detect a difference with Korean J Urol 2011;52:384-389
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such small sample sizes. At the time of the last follow-up 
after surgery, 3 patients from the cryoablation cohort 
(37.5%) and 2 patients from the PN group (33.3%) had de-
veloped CKD de novo. However, these patients had a rela-
tively lower GFR at the time of surgery than did the pa-
tients who had a normal GFR on follow-up (65 vs. 78 
ml/min/1.73 m
2). In the follow-up of patients who had CKD 
at the time of treatment, only one cryoablation patient de-
veloped additional complications of CKD in the form of hy-
pertension and diabetes, whereas two patients from the PN 
group had progression, one in the form of coronary artery 
disease with hyperlipidemia and another in the form of 
hypertension. 
　All complications that occurred during surgery or up to 
30 days after the procedure were defined as perioperative 
complications. With the widespread use of cryoablation, we 
are witnessing the emergence of many complications that 
are specific to cryoablation [30]. Two complications in the 
form of atrial flutter (n=1) and sinus tachycardia (n=1) oc-
curred in the cryoablation patients. In the PN group, eight 
patients developed 10 perioperative complications. These 
included cardiac complications (atrial flutter [n=2], my-
ocardial infarction [n=1]), respiratory complications (pul-
monary edema [n=1], pneumonia [n=1]), ureteral transec-
tion (n=1), wound infection (n=1), flank cellulitis (n=1), 
jaundice (n=1), and bullous impetigo (n=1). Ghavamian et 
al and Saranchuk et al reported complication rates of 23.8% 
and 26%, respectively, in patients undergoing PN for soli-
tary kidney tumors [1,2]. We observed a relatively higher 
complication rate in the PN group, with 53.3% of the pa-
tients having at least one complication. By comparison 
with the cryoablation group (8.7%), complications in pa-
tients treated with PN were found to be significantly higher 
(p=0.03). Our results are in line with the data published by 
Desai et al, who reported a higher incidence of complica-
tions in the PN group than in the cryoablation group [27]. 
Turna et al published similar results with as many as 26 
perioperative complications in 36 patients undergoing PN 
as compared with 5 complications in the cryoablation group 
[29]. We also found that the PN group had more blood loss 
and a longer duration of hospital stay than did the cryoa-
blation group. Thus, cryoablation offers the option of a 
nephron-sparing modality with lower morbidity, which 
could be of particular importance in older patients who are 
considered to be poor surgical candidates [30].
　Meticulous radiological studies were done at regular in-
tervals postoperatively to look for any evidence of local or 
distant recurrence for an average follow-up of 30 months. 
Recurrence was seen in 3 patients each (13.3% and 20% in 
the cryoablation and PN groups, respectively). However, 
we found no statistically significant difference in disease 
recurrence or overall survival between the two groups. The 
three patients who witnessed a progression of disease in 
the PN cohort had a relatively larger mean tumor size of 
4.5 cm as compared to their group (PN) mean size of 3.5 cm. 
The tumors in these patients were located near the hilum, 
making complete extirpation especially difficult. Intraopera-
tively, these three patients experienced a relatively higher 
amount of EBL (mean 1,400 cc) compared with the group’s 
mean EBL of 316 cc. It is quite feasible that the large tumor 
size and the relatively inaccessible location of these tumors 
contributed to the higher intraoperative blood loss and an 
incomplete tumor excision. In the cryoablation cohort, the 
three patients who experienced disease recurrence had a 
mean tumor size of 2.1 cm, which was smaller than the 
group’s mean tumor size of 2.5 cm. However, it is note-
worthy that the tumors in these patients were also located 
near the hilum and were endophytic, located deep inside 
the kidney, making a thorough ablation relatively challen-
ging. Thus, tumor location might have contributed to dis-
ease recurrence in these patients also.
　Collectively, we have presented a comparative analysis 
of renal function and oncologic status after PN or cryoa-
blation in this uncommon cohort of patients with solitary 
kidney tumors. Our study demonstrates that in appropri-
ately selected patients, renal cryoablation has distinct ad-
vantages over PN, including a shorter hospital stay, a lower 
complication rate, and less blood loss. Also, cryoablation 
was successful in maintaining optimal renal function and 
had oncologic outcomes comparable to PN on intermediate 
follow-up. Thus, cryoablation offers the option of a neph-
ron-sparing modality with impressive renal function and 
oncologic outcomes and lower morbidity.
　We acknowledge the limitations of our study, which in-
clude among other things, the disparate tumor and sample 
sizes in the two groups. This could have been due to an in-
herent selection bias associated with the retrospective, 
nonrandomized design of our study. Older patients with co-
morbidities are considered poor surgical candidates. In 
these patients, cryoablation is preferred over PN to avoid 
the renal ischemic insult conferred by PN. Our study was 
also limited by its relatively small sample size and an inter-
mediate follow-up interval, which precludes a more com-
prehensive multivariate statistical analysis. However, tu-
mors in a solitary kidney are a relatively infrequent occur-
rence. This is also the reason the effect of the different ap-
proaches (open, laparoscopic, and percutaneous) in the two 
groups could not be accounted for in the analysis. The cur-
rent prevailing urologic literature does not include enough 
parallel studies. Therefore, pooled analyses from addi-
tional reports comprising larger datasets with longer clin-
ical follow-ups (5 and 10 years) are warranted to better de-
lineate the role of these two procedures in maintaining re-
nal function in this high-risk cohort.
CONCLUSIONS
In conclusion, the increasing frequency of detection of tu-
mors in solitary kidneys demands a better outlined strat-
egy with stricter selection criteria for effective treatment 
choice along with long-term renal function maintenance. 
Both cryoablation and PN are viable techniques with accep-
table preservation of renal function for tumors of a small 
renal mass. Although PN remains the standard of care, cry-Korean J Urol 2011;52:384-389
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oablation offers an excellent treatment alternative, with 
less morbidity, comparable oncologic and functional out-
comes, and faster recovery.
Conflicts of Interest
The authors have nothing to disclose.
REFERENCES
1. Ghavamian R, Cheville JC, Lohse CM, Weaver AL, Zincke H, 
Blute ML. Renal cell carcinoma in the solitary kidney: an analysis 
of complications and outcome after nephron sparing surgery. J 
Urol 2002;168:454-9.
2. Saranchuk JW, Touijer AK, Hakimian P, Snyder ME, Russo P. 
Partial nephrectomy for patients with a solitary kidney: the 
Memorial Sloan-Kettering experience. BJU Int 2004;94:1323-8.
3. Fergany AF, Saad IR, Woo L, Novick AC. Open partial neph-
rectomy for tumor in a solitary kidney: experience with 400 cases. 
J Urol 2006;175:1630-3.
4. Davol PE, Fulmer BR, Rukstalis DB. Long-term results of cryoa-
blation for renal cancer and complex renal masses. Urology 2006; 
68(1 Suppl):2-6.
5. Aron M, Kamoi K, Remer E, Berger A, Desai M, Gill I. Laparosco-
pic renal cryoablation: 8-year, single surgeon outcomes. J Urol 
2010;183:889-95.
6. Mues AC, Landman J. Results of kidney tumor cryoablation: re-
nal function preservation and oncologic efficacy. World J Urol 
2010;28:565-70.
7. Shingleton WB, Sewell PE Jr. Cryoablation of renal tumours in 
patients with solitary kidneys. BJU Int 2003;92:237-9.
8. Gill IS, Novick AC, Soble JJ, Sung GT, Remer EM, Hale J, et al. 
Laparoscopic renal cryoablation: initial clinical series. Urology 
1998;52:543-51.
9. Uchida M, Imaide Y, Sugimoto K, Uehara H, Watanabe H. 
Percutaneous cryosurgery for renal tumours. Br J Urol 1995;75: 
132-6.
10. Delworth MG, Pisters LL, Fornage BD, von Eschenbach AC. 
Cryotherapy for renal cell carcinoma and angiomyolipoma. J Urol 
1996;155:252-4.
11. Novick AC. Nephron-sparing surgery for renal cell carcinoma. 
Annu Rev Med 2002;53:393-407.
12. Gill IS, Desai MM, Kaouk JH, Meraney AM, Murphy DP, Sung 
GT, et al. Laparoscopic partial nephrectomy for renal tumor: du-
plicating open surgical techniques. J Urol 2002;167:469-7.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method 
of classifying prognostic comorbidity in longitudinal studies: de-
velopment and validation. J Chronic Dis 1987;40:373-83.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more 
accurate method to estimate Glomerular filtration rate from se-
rum creatinine. A new prediction equation. Ann Intern Med 1999; 
130:461-70.
15. Park H, Byun SS, Kim HH, Lee SB, Kwon TG, Jeon SH, et al. 
Comparison of laparoscopic and open partial nephrectomies in 
T1a renal cell carcinoma: a Korean multicenter experience. 
Korean J Urol 2010;51:467-71.
16. Lane BR, Babineau DC, Poggio ED, Weight CJ, Larson BT, Gill 
IS, et al. Factors predicting renal functional outcome after partial 
nephrectomy. J Urol 2008;180:2363-8.
17. Beri A, Lattouf JB, Deambros O, Grüll M, Gschwendtner M, 
Ziegerhofer J, et al. Partial nephrectomy using renal artery perfu-
sion for cold ischemia: functional and oncologic outcomes. J 
Endourol 2008;22:1285-90. 
18. Inoue Y, Kurimoto S, Kameyama S, Ohta N, Akahane M, 
Yoshikawa K, et al. Prolonged renal parenchymal retention of 
99mTc mercaptoacetyltriglycine after nephron-sparing surgery. 
Nucl Med Commun 2004;25:509-13. 
19. Janetschek G, Daffner P, Peschel R, Bartsch G. Laparoscopic 
nephron sparing surgery for small renal cell carcinoma. J Urol 
1998;159:1152-5.
20. Thompson RH, Lane BR, Lohse CM, Leibovich BC, Fergany A, 
Frank I, et al. Comparison of warm ischemia vs. no ischemia dur-
ing partial nephrectomy on a solitary kidney. Eur Urol 2010;58: 
331-6.
21. Ham BK, Kang SG, Choi H, Ko YH, Kang SH, Cheon J. The impact 
of renal tumor size on the efficacy of laparoscopic renal cryo-
ablation. Korean J Urol 2010;51:171-7. 
22. Campbell SC, Novick AC. Surgical technique and morbidity of 
elective partial nephrectomy. Semin Urol Oncol 1995;13:281-7.
23. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kid-
ney disease and the risks of death, cardiovascular events, and 
hospitalization. N Engl J Med 2004;351:1296-305.
24. Poggio ED, Nef PC, Wang X, Greene T, Van Lente F, Dennis VW, 
et al. Performance of the Cockcroft-Gault and modification of diet 
in renal disease equations in estimating GFR in ill-hospitalized 
patients. Am J Kidney Dis 2005;46:242-52.
25. Levey AS, Lesley AS, Schmid CH, Zhang YL, Castro AF 3rd, 
Feldman HI, et al. A new equation to estimate glomerular filtra-
tion rate. Ann Intern Med 2009;150:604-12.
26. Matsushita K, Selvin E, Bash LD, Astor BC, Coresh J. Risk im-
plications of the new CKD Epidemiology Collaboration (CKD- 
EPI) equation compared with the MDRD Study equation for esti-
mated GFR: The Atherosclerosis Risk in Communities (ARIC) 
Study. Am J Kidney Dis 2010;55:648-59.
27. Desai MM, Aron M, Gill IS. Laparoscopic partial nephrectomy 
versus laparoscopic cryoablation for the small renal tumor. 
Urology 2005;66(5 Suppl):23-8.
28. O'Malley RL, Berger AD, Kanofsky JA, Phillips CK, Stifelman M, 
Taneja SS. A matched-cohort comparison of laparoscopic cryoa-
blation and laparoscopic partial nephrectomy for treating renal 
masses. BJU Int 2007;99:395-8.
29. Turna B, Kaouk JH, Frota R, Stein RJ, Kamoi K, Gill IS, et al. 
Minimally invasive nephron sparing management for renal tu-
mors in solitary kidneys. J Urol 2009;182:2150-7.
30. Sidana A, Agarwal P, Feng Z, Georgiades CS, Trock BJ, Rodriguez 
R. Complications of renal cryoablation: a single center experience. 
J Urol 2010;184:42-7.